Drugs, Bpco: Tozorakib Reduces Exacerbations in 2 Phase 3 Studies
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.5 Articles
5 Articles
Il Tempo
Milan, 9 Sep. (Adnkronos Salute) - The complete results of phase 3 studies Oberon and Titania showed that tozorakib, a monoclonal antibody potential first in class acting by inhibiting interleukin 33 (Il-33), is the first biological drug to demonstrate statistically significant efficacy and high clinical relevance in reducing moderate to severe exacerbations in a large population of patients with chronic obstructive pulmonary disease (Bpco) who …
The complete results of phase 3 studies Oberon and Titania have shown that tozorakib, a monoclonal antibody potential first in class acting by inhibiting interleukin 33 (Il-33), is the first biological drug to demonstrate statistically significant efficacy and of high clinical relevance in reducing moderate to severe exacerbations in a large population [...]
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
